Urine S-Adenosylmethionine are Related to Degree of Renal Insufficiency in Patients with Chronic Kidney Disease.

Autor:	Kruglova MP; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Ivanov AV; Department of Molecular and Cell Pathophysiology, Institute of General Pathology and Pathophysiology, Moscow, Russia., Virus ED; Department of Molecular and Cell Pathophysiology, Institute of General Pathology and Pathophysiology, Moscow, Russia., Bulgakova PO; Department of Molecular and Cell Pathophysiology, Institute of General Pathology and Pathophysiology, Moscow, Russia., Samokhin AS; Department of Molecular and Cell Pathophysiology, Institute of General Pathology and Pathophysiology, Moscow, Russia., Fedoseev AN; City Clinical Hospital No. 24 of Moscow Healthcare Department, Moscow, Russia., Grachev SV; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Kubatiev AA; Department of Molecular and Cell Pathophysiology, Institute of General Pathology and Pathophysiology, Moscow, Russia.; Russian Medical Academy of Postdoctoral Education, Moscow, Russia.
Jazyk:	angličtina
Zdroj:	Laboratory medicine [Lab Med] 2021 Jan 04; Vol. 52 (1), pp. 47-56.
DOI:	10.1093/labmed/lmaa034
Abstrakt:	Objective: To determine whether urine S-adenosylmethionine (SAM) might be an indicator of chronic kidney disease (CKD). Methods: We investigated urine levels of SAM and related metabolites (S-adenosylhomocysteine and homocysteine cysteine) in 62 patients (average age, 65.9 years) with CKD (stages II-V). Results: Patients with stages III-V CKD stages have significantly decreased urine levels and SAM/S-adenosylhomocysteine ratio and also cysteine/homocysteine ratio in blood plasma (P <.05), compared with patients with stage II CKD. Urine SAM levels allowed us to distinguish patients with mildly decreased kidney function from those with moderate to severe renal impairment (AUC, 0.791; sensitivity, 85%; specificity, 78.6%). Conclusions: Our study results demonstrate that urine SAM is a potent biomarker for monitoring renal function decline at early CKD stages. Urine SAM testing confers an additional advantage to healthcare professionals in that it is noninvasive. (© American Society for Clinical Pathology 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu